X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with Dishman Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs DISHMAN PHARMA - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. DISHMAN PHARMA FRESENIUS KABI ONCO./
DISHMAN PHARMA
 
P/E (TTM) x 22.1 25.1 88.2% View Chart
P/BV x 3.1 3.3 93.0% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 FRESENIUS KABI ONCO.   DISHMAN PHARMA
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
DISHMAN PHARMA
Mar-16
FRESENIUS KABI ONCO./
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs176374 47.0%   
Low Rs79129 60.9%   
Sales per share (Unadj.) Rs37.7197.8 19.1%  
Earnings per share (Unadj.) Rs5.121.2 24.0%  
Cash flow per share (Unadj.) Rs6.734.7 19.4%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs42.5179.9 23.6%  
Shares outstanding (eoy) m158.2380.69 196.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.41.3 265.4%   
Avg P/E ratio x25.011.9 210.5%  
P/CF ratio (eoy) x18.97.2 261.2%  
Price / Book Value ratio x3.01.4 213.8%  
Dividend payout %09.4 0.0%   
Avg Mkt Cap Rs m20,13520,306 99.2%   
No. of employees `0001.20.8 139.0%   
Total wages/salary Rs m7035,355 13.1%   
Avg. sales/employee Rs Th5,176.219,252.7 26.9%   
Avg. wages/employee Rs Th610.46,459.5 9.4%   
Avg. net profit/employee Rs Th699.62,064.1 33.9%   
INCOME DATA
Net Sales Rs m5,96315,961 37.4%  
Other income Rs m18265 6.8%   
Total revenues Rs m5,98116,226 36.9%   
Gross profit Rs m1,4304,103 34.9%  
Depreciation Rs m2581,091 23.6%   
Interest Rs m-26944 -2.8%   
Profit before tax Rs m1,2162,334 52.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m342624 54.9%   
Profit after tax Rs m8061,711 47.1%  
Gross profit margin %24.025.7 93.3%  
Effective tax rate %28.126.7 105.3%   
Net profit margin %13.510.7 126.1%  
BALANCE SHEET DATA
Current assets Rs m5,10211,018 46.3%   
Current liabilities Rs m2,3859,517 25.1%   
Net working cap to sales %45.69.4 484.4%  
Current ratio x2.11.2 184.7%  
Inventory Days Days150110 135.8%  
Debtors Days Days11335 325.2%  
Net fixed assets Rs m5,14816,304 31.6%   
Share capital Rs m158161 98.0%   
"Free" reserves Rs m6,55612,907 50.8%   
Net worth Rs m6,73214,516 46.4%   
Long term debt Rs m9524,189 22.7%   
Total assets Rs m10,38829,805 34.9%  
Interest coverage x-45.83.5 -1,318.8%   
Debt to equity ratio x0.10.3 49.0%  
Sales to assets ratio x0.60.5 107.2%   
Return on assets %7.58.9 84.3%  
Return on equity %12.011.8 101.6%  
Return on capital %14.617.5 83.3%  
Exports to sales %74.524.8 300.4%   
Imports to sales %24.83.7 663.2%   
Exports (fob) Rs m4,4413,956 112.2%   
Imports (cif) Rs m1,477596 247.8%   
Fx inflow Rs m5,2984,952 107.0%   
Fx outflow Rs m1,772697 254.3%   
Net fx Rs m3,5254,255 82.9%   
CASH FLOW
From Operations Rs m1,2742,786 45.7%  
From Investments Rs m-1,204-1,529 78.8%  
From Financial Activity Rs m-196-941 20.8%  
Net Cashflow Rs m-126316 -39.9%  

Share Holding

Indian Promoters % 0.0 61.4 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 3.7 8.1%  
FIIs % 9.6 12.7 75.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 22.1 41.2%  
Shareholders   42,599 46,261 92.1%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   SHASUN PHARMA  WYETH LTD  ABBOTT INDIA  ALEMBIC LTD  DR. REDDYS LAB  

Compare FRESENIUS KABI ONCO. With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 5-YR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS